Life Technologies Offers Early Access for Japanese Market to New BenchPro 2100 MaxiCard Plasmid Purification Instrument
by Patty Zamora - 06/30/10
Worldwide launch of system to occur August 2010
[TOKYO, JAPAN] -- June 30, 2010 — Life Technologies Corporation (NASDAQ: LIFE), today announced it is launching an early access program in Japan for its new BenchPro® 2100 MaxiCard™ plasmid purification instrument during the 9th International Bio Forum & Bio Expo Japan, occurring June 30 to July 2. The system is a fully automated instrument that allows users to go from cell culture to purified plasmid with the push of a button.
Today, the traditional methods for the purification of plasmid DNA use manual based spin or vacuum columns to purify plasmids which generally requires one hour of hand-on time and up to three hours of sample processing time. The BenchPro 2100 MaxiCard, using the gravity-based columns, fully automates this tedious yet crucial process, allowing researchers to purify up to 1 milligram of transfection-grade plasmids with less than five minutes of hands-on setup time followed by about 90 minutes of instrument processing time. The instrument also allows for the parallel processing of two maxipreps straight from the bacterial culture.
“We are proud to be the first country to have access to this new instrument and so with this launch in Japan, we’ve brought plasmid purification into the twenty-first century and can now offer our customers even more significant improvements to plasmid purification efficiencies,” said Siddhartha Kadia Ph.D., President of Life Technologies Japan. “In our experience, scientists in Japan are excellent at adopting new technologies that will make their experiments faster and simpler. BenchPro 2100 MaxiCard is part of our growing portfolio of bench top device products such as the Neon Transfection System and the Countess Automated Cell Counter, both of which are already being used in Japan. Plasmid DNA purification is absolutely necessary for a wide range of biological studies and we are delighted to provide this new alternative to support more Japanese scientists in their labs.”
About Life Technologies (http://www.lifetechnologies.com)
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.
Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contacts
Eriko Takahata (Japan)
Patty Zamora (U.S)